Clinical Trial

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy. Adjuvant chemotherapy with ifosfamide and doxorubicin may improve long-term disease-free survival, but the benefit of adjuvant treatment is limited and predictive factors for treatment response are lacking. The aim of this study is to explore sequential treatment with ifosfamide and doxorubicin in a neoadjuvant setting and to investigate biomarkers predictive of treatment response.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-02-26; most recent amendment 2025-08-11.
Status change: Not Yet Recruiting → Recruiting 2021-03-15
Trial Details
NCT Number NCT04776525
Lead Sponsor Oslo University Hospital
Collaborators: Haukeland University Hospital
Conditions Soft Tissue Sarcoma
Enrollment 49 participants
Start Date 2021-04-27
Primary Completion 2026-09 (estimated)
Study Completion 2036-09 (estimated)
Updated on ClinicalTrials.gov 2025-08-14